IV Iron Management in Hemodialysis Patients

Initiation Criteria

• Begin intravenous iron when ferritin is ≤ 200 ng/mL or transferrin saturation (TSAT) is ≤ 20 % (including patients with ferritin 200–800 ng/mL who have functional iron deficiency) – Kidney International 2023. [1][2]

• A TSAT < 20 % threshold demonstrates high sensitivity for detecting both absolute and functional iron deficiency in dialysis patients – American Journal of Hematology 2024. 3

Target Parameters (Maintenance Goals)

• Maintain serum ferritin between 200 ng/mL and 800 ng/mL during chronic therapy – Kidney International 2023. 1

• Maintain TSAT between 20 % and 40 % to optimize iron availability – Kidney International 2023. [1][2]

Dosing Recommendations (General Guidance)

• For hemodialysis patients, administer 100–200 mg of intravenous iron each month when ferritin ≤ 200 ng/mL or TSAT ≤ 20 %; the therapeutic aim is to keep ferritin 200–800 ng/mL and TSAT 20–40 % – Kidney International 2023. [1][2]

Stopping / Holding Criteria

• Hold intravenous iron when ferritin reaches ≥ 800 ng/mL and TSAT is ≥ 20 % – Kidney International 2023. [1][2]

• Hold iron when TSAT is ≥ 40 % regardless of ferritin level – Kidney International 2023. [1][2]

Monitoring Schedule

• Re‑measure iron parameters (ferritin, TSAT) 4–8 weeks after any dose adjustment to assess response – American Journal of Hematology 2024. 3

• Do not check ferritin within 4 weeks of an intravenous iron dose because circulating iron can cause falsely elevated results – American Journal of Hematology 2024. 3

Formulation‑Specific Dosing

These dosing limits are supported by data from the American Journal of Hematology 2024. 3

Interpretation of Iron Markers in the Context of Inflammation

• Ferritin is an acute‑phase reactant and may be elevated by inflammation even when true iron deficiency exists – American Journal of Hematology 2024. 3

• In cases where ferritin is high but TSAT is low, TSAT provides a more reliable guide for iron therapy decisions – American Journal of Hematology 2024. 3

Test Dosing Considerations

• Newer iron formulations (ferric carboxymaltose, ferumoxytol, ferric derisomaltose) generally do not require a test dose before full administration – American Journal of Hematology 2024. 3

Iron Therapy in Chronic Kidney Disease

Introduction to Iron Management

• The American Journal of Kidney Diseases recommends initiating iron therapy in patients with chronic kidney disease when serum ferritin is <100 ng/mL or when ferritin is between 100-800 ng/mL with transferrin saturation (TSAT) <20% 4, 5

Soglie Specifiche per Popolazione

• For patients on hemodialysis (HD-CKD), the National Kidney Foundation suggests starting iron therapy when ferritin ≤200 ng/mL or TSAT ≤20% 4, 5, 6
• The Kidney International Supplements guideline recommends maintaining ferritin >200 ng/mL and TSAT >20% to reduce the doses of erythropoietin needed 6, 7

Carenza Funzionale vs Assoluta

• The American Journal of Kidney Diseases defines functional iron deficiency as TSAT ≤20% with elevated ferritin (>100 ng/mL but <800 ng/mL) 4, 5
• Functional iron deficiency is caused by increased levels of hepcidin that prevent iron mobilization 4, 5

Algoritmo Pratico di Gestione

• The American Journal of Kidney Diseases recommends measuring serum ferritin and TSAT every 3 months and evaluating them jointly with hemoglobin levels and ESA dose 4, 5, 6
• For HD-CKD patients, if ferritin ≤200 ng/mL or TSAT ≤20%, initiate intravenous iron therapy 6

Considerazioni sulla Sicurezza

• The American Journal of Kidney Diseases suggests a test dose of 25 mg of intravenous iron dextran in adults before starting therapy 4
• The risk of bacterial infections is not increased with current guidelines, but monitoring is still necessary 5

IV Iron Management for Hemodialysis Patients

Initiation Criteria

• The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF‑K/DOQI) guidelines recommend starting intravenous iron when ferritin is ≤ 100 ng/mL or transferrin saturation (TSAT) is ≤ 20% in adult hemodialysis patients【8】.

Target Iron Parameters

• Maintaining ferritin between 200 ng/mL and 800 ng/mL and TSAT between 20 % and 40 % balances adequate iron availability with the risk of iron overload, as supported by clinical evidence【9】【10】.
• Observational data show that ferritin concentrations of 300–800 ng/mL are common in dialysis populations and have not been linked to adverse iron‑mediated outcomes【8】【9】.

Dosing Regimens

• The above dosing options are derived from peer‑reviewed studies and provide practical equivalents for monthly iron administration in hemodialysis patients【11】【12】【13】.

Holding or Stopping IV Iron

• Iron therapy should be withheld when ferritin reaches ≥ 800 ng/mL and TSAT is ≥ 20%, because further hemoglobin improvement or ESA dose reduction is unlikely beyond this ferritin level【11】【13】.
• TSAT values ≥ 40% should trigger a hold of iron regardless of ferritin, as there is no physiologic rationale for maintaining TSAT above this threshold【8】【9】.

Monitoring Schedule

• Ferritin and TSAT should be measured every three months during stable maintenance therapy to guide dose adjustments【8】【9】.

Test Dosing Requirements

• Iron dextran requires a one‑time 25 mg test dose before initiating therapy in adults, based on safety data【8】【9】【10】.
• Iron gluconate also recommends a single 25 mg test dose prior to full treatment【9】【10】.
• Newer IV iron formulations (e.g., ferric carboxymaltose, ferumoxytol, ferric derisomaltose) generally do not require test dosing (no citation needed).

Safety Considerations – Dose‑Related Toxicity

• Observational studies have linked sustained monthly iron doses > 200 mg for > 1 year with increased mortality and cardiovascular events【12】.
• The DOPPS observational cohort reported higher mortality risk (hazard ratio 1.13–1.18) with monthly iron doses > 300 mg【12】.
• Japanese registry data indicated a markedly increased risk of acute cardiocerebrovascular disease (hazard ratio 6.02) when monthly iron dosing exceeded 200 mg【12】.

These safety signals are derived from observational evidence and should be weighed against the benefits of iron repletion, especially in patients with high ESA requirements.